HMPL-760 for Waldenstrom Macroglobulinemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Waldenstrom Macroglobulinemia+10 More
HMPL-760 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, HMPL-760, on patients who have already been treated for a type of cancer called CLL/SLL or NHL. They're testing how safe and tolerable the drug is, as well as its efficacy.

Eligible Conditions
  • Waldenstrom Macroglobulinemia
  • MCL
  • MZL
  • Lymphoplasmacytic Lymphoma
  • Richter's Syndrome
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Non-Hodgkin's Lymphoma (NHL)
  • Lymphoma, Follicular

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

4 Primary · 7 Secondary · Reporting Duration: From 1st dose of study drug to the time of progressive disease, assessed up to 36 months

Month 36
Clinical Benefit Rate (CBR)
Objective Response Rate (ORR)
Progression-free Survival (PFS)
Day 30
Chemokines
Incidence of AEs/SAEs
MTD
Maximum Plasma Concentration [Cmax]
Phospho-BTK
RP2D
Month 36
Duration of Response (DoR)
Day 28
Incidence of DLTs

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

3 Treatment Groups

Part 1 Dose Escalation Cohorts
1 of 3
Part 2 Dose Expansion Cohorts
1 of 3
Treatment
1 of 3

Experimental Treatment

168 Total Participants · 3 Treatment Groups

Primary Treatment: HMPL-760 · No Placebo Group · Phase 1

Part 1 Dose Escalation Cohorts
Drug
Experimental Group · 1 Intervention: HMPL-760 · Intervention Types: Drug
Part 2 Dose Expansion Cohorts
Drug
Experimental Group · 1 Intervention: HMPL-760 · Intervention Types: Drug
Treatment
Drug
Experimental Group · 1 Intervention: HMPL-760 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from 1st dose of study drug to the time of progressive disease, assessed up to 36 months

Who is running the clinical trial?

HutchmedLead Sponsor
13 Previous Clinical Trials
1,009 Total Patients Enrolled
Hutchison Medipharma LimitedLead Sponsor
99 Previous Clinical Trials
13,610 Total Patients Enrolled
Vijay Jayaprakash, MBBS, PHDStudy DirectorHutchison Medipharma Limited
1 Previous Clinical Trials
75 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.